Revolution Medicines CEO Mark Goldsmith on new Pancreatic cancer drug breakthrough

Revolution Medicines CEO Mark Goldsmith sits down with CNBC's Angelica Peebles at the American Society of Clinical Oncology's annual meeting to discuss its new Pancreatic cancer drug breakthrough, submitting FDA application for the drug, and more.